$110.34
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Mizuho Raises Price Target on Kymera Therapeutics to $140 From $120, Keeps Outperform Rating
Kymera Therapeutics Shares Fall After RBC Downgrade
RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk
Overview
52-week range
$37
$103
100% of range
Avg surprise (last 2)
-1.8%
Avg reaction (last 1)
-2.3%
0% positive
Latest IV / EM
62%
EM ±14.3% · $110 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.71 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.94 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.95 | $-0.83 | -14.5% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.82 | $-0.92 | +10.9% | — | -2.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.82 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.58 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.69 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.90 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.67 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.64 | -$0.95 | +32.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34M | — | $3M | $11M | $22M | — | $4M | $26M |
| Cost of revenue | $34M | — | $3M | $11M | $22M | — | $4M | $26M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-84M | — | $-93M | $-85M | $-74M | — | $-72M | $-51M |
| Net income | $-69M | — | $-82M | $-77M | $-66M | — | $-62M | $-42M |
| EPS (diluted) | $-0.71 | — | $-0.94 | $-0.95 | $-0.82 | — | $-0.82 | $-0.58 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $144M | $357M | $113M | $336M | $90M | $120M | $111M | $68M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $677M | $871M | $528M | $728M | $501M | $510M | $569M | $525M |
| Total assets | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $129M | $163M | $156M | $160M | $132M | $142M | $142M | $141M |
| Total equity | $1.54B | $1.58B | $946M | $971M | $786M | $836M | $893M | $685M |